Skip to main content

Table 2 The tumor volume with anti-CD25 and/or anti-TGF-β treatment in different periods

From: CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer

Cohorts Number Day 7 (p value) Day 14 (p value) Day 21 (p value) Day 28 (p value) Day 35 (p value)
Control 5 9.92 ± 5.82 (1) 38.30 ± 29.00 (1) 259.43 ± 171.47 (1) 942.92 ± 745.58 (1) 1962.19 ± 1326.31 (1)
Anti-TGF-β 5 5.19 ± 4.00 (0.142) 14.60 ± 9.08 (0.056) 63.57 ± 40.38 (0.053) 487.30 ± 530.90 (0.353) 984.64 ± 719.09 (0.211)
Anti-CD25 5 2.22 ± 2.90 (0.012) 3.97 ± 4.28 (0.005) 90.74 ± 123.26 (0.104) 257.59 ± 310.82 (0.104) 774.40 ± 867.07 (0.108)
Anti-TGF-β+ anti-CD25 6 0.01 ± 0.004 (0.001) 0.46 ± 0.85 (0.002) 48.31 ± 115.88 (0.028) 120.39 ± 288.12 (0.035) 160.81 ± 347.21 (0.008)
  1. Italic values indicate significance of p value (p<0.05)